Clinical Trials on Multiple Endocrine Neoplasia, Type 3

Total 59379 results

Eli Lilly and Company
BioMS Technology Corp.

Terminated

A Study for Patients With Multiple Sclerosis (MAESTRO-02)

Secondary Progressive Multiple Sclerosis

Canada, Estonia, Denmark, Finland, Latvia, Spain, Sweden, United Kingdom, Germany, Netherlands
Eli Lilly and Company
BioMS Technology Corp.

Completed

A Study for Patients With Secondary Progressive Multiple Sclerosis (MAESTRO-01)

Secondary Progressive Multiple Sclerosis

Canada, Estonia, Denmark, Finland, Germany, Latvia, Netherlands, Spain, Sweden, United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating Mitoxantrone in Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

Germany
National Cancer Institute (NCI)

Active, not recruiting

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
Hospital Universitario Dr. Jose E. Gonzalez

Unknown

Autologous Stem Cells in Newborns With Oxygen Deprivation

Multiple Organ Failure | Hypoxia, Brain | Metabolic Acidosis | Apgar; 0-3 at 1 Minute

Mexico
Kyverna Therapeutics

Not yet recruiting

A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive
University of Utah

Completed

Novel Imaging Markers in SPMS

Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Secondary Progressive Multiple Sclerosis

United States
National Cancer Institute (NCI)

Recruiting

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple Myeloma | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Newly Diagnosed Multiple Myeloma (NDMM)

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Plasmacytoma | Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Peng Liu
Shanghai East Hospital; Hrain Biotechnology

Unknown

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Tehran University of Medical Sciences

Completed

Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis (MS)

Multiple Sclerosis | Mesenchymal Stem Cells | Secondary-Progressive Multiple Sclerosis

Iran, Islamic Republic of
National Cancer Institute (NCI)

Active, not recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
HealthTree Foundation

Recruiting

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM)

Multiple Myeloma, Smoldering

United States
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Smoldering Multiple Myeloma (SMM)

Spain
Omar Nadeem, MD
Janssen, LP

Recruiting

DARA RVD For High Risk SMM (PRISM)

Multiple Myeloma | High-risk Smoldering Multiple Myeloma

United States
Icahn School of Medicine at Mount Sinai
Pharmacyclics LLC.

Terminated

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

High Risk Smoldering Multiple Myeloma

United States
University of Arkansas
Millennium Pharmaceuticals, Inc.

Completed

UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

Asymptomatic Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Mayo Clinic
University of Iowa

Completed

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Temple University

Completed

High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Innate Immunotherapeutics
Syneos Health

Completed

Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

New Zealand, Australia
Biogen

Terminated

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis (INSPIRE)

Multiple Sclerosis, Secondary Progressive

United States, Poland, Belgium, Slovakia, Czech Republic, Netherlands
Biogen

Withdrawn

Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

Secondary Progressive Multiple Sclerosis
University College London Hospitals

Completed

A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

United Kingdom
University Medical Center Groningen
Dutch Cancer Society; ViciniVax B.V

Completed

Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions

Cervical Cancer | CIN 2/3

Netherlands

Clinical Trials on Multiple Endocrine Neoplasia, Type 3

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations